Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity
The DOI matches its Crossref record.
Abstract
Insulin-like growth factor binding protein-3 (IGFBP-3) is the major carrier of insulin-like growth factor I (IGF-1) in serum, and its production is growth hormone (GH) dependent. It is unclear whether in humans IGFBP-3 production is directly regulated by GH or mediated via IGF-I. We addressed this question in six patients with Laron-type dwarfism, a syndrome characterized by the absence of GH receptor activity (LTD), who were chronically treated with recombinant IGF-I. Analysis of the electrophoretic profiles of serum IGFBPs in these patients by Western ligand blotting revealed an extremely low IGFBP-3 level. A striking progressive increase in serum IGFBP-3 was observed with continuous treatment, despite the absence of GH action. In LTD children, serum IGFBP-3 increased up to 19-fold after six months of therapy and equalled levels observed in controls, whereas in adult LTD patients the increase was smaller. A rise in serum levels of 34, 30 and 24 kDa BPs (presumably IGFBP-2, -1 and -4, respectively was also noted with chronic IGF-I therapy. This proof of GH-independent induction of IGFBP-3 by IGF-1 may be a major advantage in the therapeutic use of biosynthetic IGF-I in several types of short stature children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rajaram, S., Baylink, D. J., & Mohan, S. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0321 · Cited by 1,097
Insulin-like growth factor 1 (IGF-1): a growth hormone
Laron, Z. (2001) · Molecular Pathology · doi:10.1136/mp.54.5.311 · Cited by 608
Self-citationLaron, Z. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031033 · Cited by 408
Self-citationDehkhoda, F., Lee, C. M. M., Medina, J., & Brooks, A. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00035 · Cited by 304
Insulin-Like Growth Factor Binding Proteins: New Proteins, New Functions
Ferry Jr., R. J., Cerri, R. W., & Cohen, P. (1999) · Hormone Research in Paediatrics · doi:10.1159/000023315 · Cited by 205
“However, in a similar population from Israel, IGF-I increased levels of IGFBP-3 by Western ligand blotting (unfortunately, this study did not utilize IGFBP-3 RIA) [”
BackgroundPerspectives in mammalian IGFBP-3 biology: local vs. systemic action
Yamada, P. M., & Lee, K.-W. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00598.2008 · Cited by 177
“Chronic IGF-1 treatment of GH insensitivity increased serum IGFBP-3 in patients (130), whereas additional studies failed to show increases in IGFBP-3 concentrations (98, 144).”
BackgroundCellular Actions of Insulin-Like Growth Factor Binding Proteins
Ferry, R., Katz, L., Grimberg, A., Cohen, P., & Weinzimer, S. (1999) · Hormone and Metabolic Research · doi:10.1055/s-2007-978719 · Cited by 166
Laron, Z. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6255 · Cited by 96
“Long-term IGF-I administration raises serum IGF binding protein-3 levels (64) and, thus, prolonging the biological half-time of IGF-I (Fig.”
BackgroundSelf-citationInsulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment
de la Garza, R. G., Morales-Garza, L. A., Martin-Estal, I., & Castilla-Cortazar, I. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2761w · Cited by 55
“IGFBP-3, which binds 90% of circulating IGF-1, forms a ternary complex consisting of one molecule of IGF-1, one molecule of IGFBP3 and one molecule of the so-called acid labile subunit [31].”
BackgroundInfluential
Metadata
- Authors
- Kanety, H., Karasik, A., Klinger, B., Silbergeld, A., & Laron, Z.
- Venue
- Acta Endocrinologica
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-02
- Volume
- 128
- Issue
- 2
- Pages
- 144-149
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2078978316
- Cited by
- 59
- References
- 0
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.